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Deficiency of TLR4 homologue 
RP105 aggravates outward 
remodeling in a murine model of 
arteriovenous fistula failure
Taisiya Bezhaeva1,2, ChunYu Wong1,3, Margreet R. de Vries  2,3, Eric P. van der Veer1,2, 
Carla M. A. van Alem1,2, Ivo Que4, Reshma A. Lalai1,2, Anton-Jan van Zonneveld1,2, Joris I. 
Rotmans1,2 & Paul H. A. Quax  2,3
Arteriovenous access dysfunction is a major cause of morbidity for hemodialysis patients. The 
pathophysiology of arteriovenous fistula (AVF) maturation failure is associated with inflammation, 
impaired outward remodeling (OR) and intimal hyperplasia. RP105 is a critical physiologic regulator of 
TLR4 signaling in numerous cell types. In the present study, we investigated the impact of RP105 on 
AVF maturation, and defined cell-specific effects of RP105 on macrophages and vascular smooth muscle 
cells (VSMCs). Overall, RP105−/− mice displayed a 26% decrease in venous OR. The inflammatory 
response in RP105−/− mice was characterized by accumulation of anti-inflammatory macrophages, 
a 76% decrease in pro- inflammatory macrophages, a 70% reduction in T-cells and a 50% decrease 
in MMP-activity. In vitro, anti-inflammatory macrophages from RP105−/− mice displayed increased 
IL10 production, while MCP1 and IL6 levels secreted by pro-inflammatory macrophages were 
elevated. VSMC content in RP105−/− AVFs was markedly decreased. In vitro, RP105−/− venous VSMCs 
proliferation was 50% lower, whereas arterial VSMCs displayed a 50% decrease in migration, relative 
to WT. In conclusion, the impaired venous OR in RP105−/− mice could result from of a shift in both 
macrophages and VSMCs towards a regenerative phenotype, identifying a novel relationship between 
inflammation and VSMC function in AVF maturation.
The placement of an arteriovenous fistula (AVF) is currently regarded as the best available option for permanent 
vascular access in patients requiring chronic hemodialysis. For proper maturation of the AVFs, both a major 
increase in blood flow and venous diameter are required to allow adequate hemodialysis treatment. However, 
several clinical trials have shown that the 1-year primary patency rate of AVFs does not exceed 60%, illustrating 
the fact that the need for further improvement of this access conduit is vital1, 2. AVF-related complications are 
frequently encountered shortly after AVF surgery, as 30–60% of the AVF fail to mature adequately to support 
dialysis therapy3. The exact mechanisms that lead to AVF maturation failure remain unknown, but both impaired 
outward remodeling (OR) and formation of intimal hyperplasia (IH) are regarded as primary contributors to 
this pathophysiology4. Recent studies have shown that the process of vascular adaptation after AVF creation is 
associated with an excessive inflammatory response5–8 and proliferation and migration of arterial and venous 
vascular smooth muscle cells (VSMCs) towards the intima at the site of anastomosis9–11. In view of extensive 
adverse consequences resulting from AVF failure and the subsequent burden for hemodialysis patients, there is 
increasing emphasis on pathophysiological studies aimed to unravel the complex mechanisms underlying AVF 
failure. The latter is pivotal in efforts to identify novel molecular therapeutic targets that could potentially improve 
AVF patency.
Toll-like receptor 4 (TLR4) is a well-known sentry that induces a pro-inflammatory signaling cascade12. Its 
function is modulated not only by exogenous pathogens in the context of microbial infections13, but also by 
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several endogenous stimuli in inflammatory conditions such as atherosclerosis14, 15 or during vascular remod-
eling16–19. To initiate the TLR4 signaling cascade, activation of its adaptor molecule MD2 is required which is 
responsible for the recognition of bacterial lipopolysaccharide (LPS) on the cell surface20. Due to the hierarchical 
importance of TLR4 in the innate immune response and its ubiquitous function, the signaling activity of this 
protein is firmly regulated by several regulatory molecules. One such regulator is RP105 (radioprotective 105, 
also known as CD180), a cell surface protein expressed by numerous cell types, including inflammatory cells and 
VSMCs21, 22. The structure of RP105 is evolutionarily similar to TLR4 and it associates with MD1, a MD2 homo-
logue which promotes RP105 cell surface expression23, 24. RP105–MD1 exerts dichotomous regulatory activities 
on TLR4-mediated LPS responses in a cell type-dependent fashion25. On B-cells, RP105-MD1 drives cellular 
proliferation and enhances B-cell- dependent inflammatory processes26. In contrast, in myeloid cells, RP105 acts 
as a natural antagonist of TLR4 signaling27, while the functional role in VSMCs remains poorly understood. 
Previous studies from our group have demonstrated that RP105 deficiency results in decreased atherosclerotic 
lesion formation via alterations on pro-inflammatory B-cells28 and a CCR2-dependent decrease in monocyte 
influx29. Strikingly, complete opposite effects were observed in a murine model of vein graft disease, where a 90% 
increase in graft lesion area was linked to a local increase in macrophage content and lesional levels of monocyte 
chemoattractant protein-1 (MCP1), expressed by VSMCs21. In a model of post-interventional vascular remode-
ling, artery cuff placement in RP105−/− mice resulted in increased neointima formation, which coincided with an 
increase in arterial VSMC proliferation ex vivo22.
In the context of both AVF maturation and failure, numerous cell types are involved including inflammatory 
cells and VSMCs from both the feeding artery10, 30 and local venous wall31, making it a unique model to unravel 
specific functional consequences of RP105 on remodeling in AVF.
In the present study, we aimed to elucidate the role of RP105 on AVF maturation in a murine model of AVF 
failure by assessing cell type-specific effects of RP105 deficiency, on macrophage polarization and VSMC behavior.
Results
RP105 deficiency influence AVF maturation. To investigate how differential expression of RP105 could 
influence AVF maturation, we created an AVF by an end-to-side ligation of the jugular vein to the carotid artery 
of wild- type (WT) and RP105−/−. Two weeks after surgery the tissue was processed to paraffin, and 5-µm sec-
tions were made perpendicular to the vein at 12 locations with an interval of 150 µm. Because most of the sten-
otic lesions in human AVFs occur in the venous outflow tract we analyzed first 3 consecutive venous sections 
downstream from the area closest to the anastomosis. AVF material was evaluated using morphometric and 
immunohistochemical approaches. RP105−/− mice showed a 26% smaller circumference of the external jugular 
vein compared to WT mice (P = 0.03) (Fig. 1a), indicating that RP105 deficiency impacts outward remodeling. 
As shown in Fig. 1b, diminished RP105 expression did not influence IH in the venous outflow tract of the AVF. 
Importantly, immunohistochemical staining revealed that the vast majority of intimal cells are αSMA+ in both 
WT and RP105−/− mice (Fig. 1b).
RP105 deficiency leads to reduced VSMC proliferation in AVF lesions. Given this VSMC enrich-
ment in the intimal region of mature AVF, we sought to determine the proliferation capacity of these cells immu-
nohistochemically. For this, we quantitated the amount of proliferating αSMA+/Ki67+ cells in AVF sections. 
These studies revealed a 31% decrease in αSMA+/Ki67+ VSMCs in RP105−/− mice, as compared to WT mice 
(Fig. 2a).
Since both arterial and venous VSMC might contribute to the portion of proliferating VSMC and we cannot 
discriminate between arterial and venous VSMCs in vivo, this borderline significance in the number of αSMA+/
Ki67+ VSMCs (P = 0.07) might be relevant (Fig. 2b).
Diminution of RP105 differently affects arterial and venous VSMC function. To further dissect the 
contribution of arterial and venous VSMCs to AVF maturation and failure, we elected to study the consequences 
of differential RP105 expression in arterial and venous VSMCs ex vivo. For this, we cultured explant material 
from the carotid artery and vena cava of WT and RP105−/− mice for 2 weeks. Morphologically, we observed that 
arterial VSMCs possessed an elongated phenotype, whereas venous cells had a more stellate appearance (Fig. 3a). 
Both arterial and venous VSMCs displayed characteristics of differentiated VSMCs, as confirmed by stable gene 
expression of VSMCs markers (smooth muscle α-actin (SMA), myosin heavy chain (MYHC) and calponin) after 
2 weeks of culture (Fig. 3b). The phenotypic difference and the vascular origin of arterial versus venous VSMCs 
was confirmed by assessing EphB4 expression levels, an established embryological marker of venous origin32, 33, 
which was increased in cultured venous VSMCs up to 2 weeks after isolation (Fig. 3c).
Next, we further determine expression levels of RP105 associating molecules. Interestingly, RT-PCR analysis 
of RP105 by WT VSMCs revealed a striking >100-fold increase in gene expression on venous VSMCs compared 
to arterial VSMCs (Fig. 4a). Expression of its accessory molecule MD1 was also elevated >100-fold on venous 
VSMCs isolated from both WT and RP105−/− mice (Fig. 4b). mRNA levels of inflammatory marker TLR4 was 
elevated by 48% in venous cells, as compared to arterial VSMCs (Fig. 4c). Expression of the TLR4 accessory mol-
ecule MD2 did not differ between WT and RP105−/− mice arterial and venous VSMCs (Supplementary Figure 1).
Functionally, venous VSMCs derived from RP105−/− mice displayed a 50% reduction in their rate of prolif-
eration, relative to VSMCs derived from WT mice, while arterial VSMCs proliferation was unaltered (Fig. 5a). 
In contrast, migratory capacity was reduced by 50% over a 16 h time period in arterial VSMCs derived from 
RP105−/−, venous SMCs showed no difference in migration between WT and RP105−/− mice (Fig. 5a). As VSMCs 
are also potent cytokine producers we measured amount of pro-inflammatory cytokines IL6 and MCP1 secreted 
by arterial and venous VSMCs from WT and RP105−/− mice. Although there was no difference in IL6 and 
MCP1 levels between WT and RP105−/−, venous VSMCs isolated from both WT and RP105−/− mice exhibited 
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higher inflammatory state characterized by 70% and 84% increase in IL6 secretion by WT and RP105−/− VSMCs 
respectively when compared to arterial VSMC and 57% and 61% up regulation in MCP1 levels produced by 
WT and RP105−/− VSMCs respectively when compared to arterial VSMCs (Fig. 5b). There was no difference 
in the amount of anti-inflammatory cytokine IL10 produced either by arterial or venous VSCMs from WT and 
RP105−/− VSMCs (Supplementary Figure 2).
RP105 deficiency impacts the inflammatory status of AVF infiltrating cells. To gain insight into 
the consequences of differential expression of RP105 on the inflammatory response to injury in vivo, we evalu-
ated the inflammatory cell composition of AVFs in RP105−/− and WT mice. Analysis of AVF material 2 weeks 
after surgery revealed a 76% reduction in MAC3+/CCR2+ pro-inflammatory macrophages cell number in the 
venous lesions of RP105−/− mice. Furthermore, the number of infiltrating MAC3+/CD206+ anti- inflammatory 
macrophages was increased by 35%, as compared to WT mice (Fig. 6a). The number of CD3+ T-lymphocytes in 
Figure 1. Effect of RP105 deficiency on AVF maturation in vivo. (a) Quantification of morphometric 
parameters. Decrease in vessel circumference (outward remodeling) in RP105 deficient mice was observed 14 
days after AVF creation, compared to WT. Lumen and intimal hyperplasia did not differ between RP105−/− and 
WT mice. (b) Histological staining of venous outflow tract 14 days after surgery. Weigert elastine staining was 
used to determine histomorphometrical parameters of the vessel. Circumference (internal elastic lamina area) 
was used to quantify outward remodeling (red line). Intimal hyperplasia (green arrow) measured as a difference 
between luminal area (blue line) and vessel circumference. αSMA staining shows area of intimal hyperplasia 14 
days after AVF creation. (#) intimal hyperplasia; P < 0.05; n = 11 per group. Bar = 200 μm; 100x magnification.
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Figure 2. Effect of RP105 deficiency on VSMCs proliferation in vivo. Quantification (a) and 
immunofluorescent staining (b) of αSMA+/Ki67+ cells (white arrows) revealed reduction in number of 
proliferating VSMCs in AVF lesions of RP105−/− mice compared to WT 14 days after AVF surgery. n = 11 per 
group. Bar = 100 μm.
Figure 3. In vitro cultured arterial and venous SMCs. (a) Microscopic representation of morphological 
difference between cultured arterial and venous VSMCs. Bar = 100 μm; 200x magnification. (b) VSMCs 
phenotype after 14 days in culture was confirmed by the stable mRNA expression levels of smooth muscle 
α-actin (SMA), myosin heavy chain (MHC) and calponin. (c) Stable increase in EphB4 mRNA levels was 
decreased in venous VSMCs isolated from WT and RP105−/− mice. *P < 0.05; n = 3.
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RP105−/− mice was decreased by 70% (Fig. 6b). Interestingly, we observed an enrichment of these inflammatory 
cells in the adventitial layer of the vessel (Fig. 6a,b). No changes between RP105−/− and WT mice were found in 
the number of MCP1+ cells in the AVF lesions at 2 weeks after surgery (Supplementary Figure 3). Notably, the 
distribution of the total population of macrophages in RP105−/− 2 weeks after AVF creation was skewed towards 
a tissue repair, or regenerative state. More than 90% of all MAC3+ cells were CD206+, a cell surface protein that 
defines the anti-inflammatory repair associated macrophage phenotype, whereas but 6% of these MAC3+ mac-
rophages were found to express CCR2, the pro-inflammatory macrophage marker.
MMP activity is decreased in AVF lesions of RP105 deficient mice. Matrix metalloproteinases 
(MMPs) are known for the role they play in extracellular matrix (ECM) remodeling, such as collagen and elastin. 
MMP-mediated degradation of the ECM is critically involved in vascular remodeling following AVF placement 
and during AVF maturation34. We assessed MMP activity in the lesions using in vivo near-infrared fluorescent 
imaging. We observed a two-fold reduction (6.3 ± 1.6 WT vs. 2.9 ± 0.2 RP105−/− AU) in fluorescence intensity 
indicating reduced in vivo MMP activity in RP105−/− mice as compared to WT (Fig. 7).
Macrophage-mediated cytokine production is affected by RP105 expression levels. Having 
identified that AVFs in RP105−/− mice are enriched for anti-inflammatory macrophages, we subsequently isolated 
bone marrow from WT and RP105−/− mice and polarized bone marrow-derived macrophages towards either 
pro- or anti-inflammatory phenotypes with LPS/IFN-gamma or IL4/IL13 treatment for 24 h, respectively. We 
observed an augmented inflammatory response by pro-inflammatory macrophages derived from RP105−/− mice 
as evidenced by a 40% increase in MCP1 secretion and a 73% up regulation in IL6 production, as compared to 
macrophages obtained from WT mice (Fig. 8a).
Macrophages that were isolated from RP105−/− mice and driven towards the anti-inflammatory phenotype 
exhibited a 72% increase in anti-inflammatory cytokine IL10 production as compared to WT macrophages 
(Fig. 8b).
RP105 is present in the venous wall of human AVF. Human AVF was obtained in the operating room 
during AVF correction surgery and processed in the same manner as mouse samples. Immunohistochemical 
staining of human AVF sections showed an impressive accumulation of RP105 expression within the venous wall. 
Cells positive for RP105 were mainly located in the neointima (Fig. 9).
Figure 4. Difference in mRNA expression levels between arterial and venous VSMCs in vitro. (a) RP105, (b) 
MD1, (c) TLR4. The relative expression normalized to GAPDH. *P < 0.05; n = 3.
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Discussion
In this study, we addressed the specific role of TLR4 homologue RP105 in vascular remodeling, inflammation 
and VSMCs function in a murine model of AVF failure. The process of AVF maturation is complex and integrates 
several cellular responses, including the infiltration of inflammatory cells shortly after AVF surgery5, 35. In addi-
tion, VSMCs play a pivotal role in AVF maturation as they contribute to thickening of the venous vessel wall and 
the concurrent outward remodeling. Here, we clearly show that RP105 deficiency affects the inflammatory and 
VSMC-mediated response to injury during the course of AVF maturation, accumulating in an impaired outward 
remodeling 14 days after the placement of an AVF.
A vital aspect of AVF maturation involves the outward remodeling response, a vessel widening process that 
is tightly coupled with VSMC proliferation. While VSMC proliferation in IH is generally considered to be detri-
mental, the process is beneficial for vascular adaptation in AVF, especially in the early phase of AVF maturation. 
To this end, the reduction in venous outward remodeling in RP105−/− mice, coupled with a reduction in prolifer-
ating venous VSMC within AVFs and ex vivo, suggests that inhibiting VSMCs proliferation (and migration) could 
be detrimental for long-term AVF maturation.
A striking observation in our studies was that RP105 diminution differentially affected arterial and venous 
VSMCs, as evidenced by RP105-specific effects on proliferation and inflammatory cytokine production by venous 
cells as well as impact on arterial migration. The endogenous expression levels of RP105 in arterial and venous 
VSMCs support this finding, along with differential expression profiles of associating TLR4-family members 
(including TLR4 and MD-1). Collectively, these findings suggest that the susceptibility for inflammatory stimuli 
could potentially differ between arterial and venous VSMCs. Importantly, our studies support the notion that 
numerous cell sources are involved in venous IH in AVF (including resident venous cells, infiltrating arterial 
cells, and circulating bone marrow-derived cells7, 36–39). Furthermore, our studies illustrate the need for continued 
investigation of the phenotypic properties and functional characteristics of VSMCs in AVFs, in particular due to 
the contrasting lineage tracing studies detailing a predominance of arterial VSMCs10 versus venous VSMCs31 in 
venous IH following AVF placement.
Figure 5. Functional difference between arterial and venous VSMCs in vitro. Reduction in proliferation 
rate was limited to VSMCs isolated from RP105−/− veins. Decrease in migration of VSMCs isolated from 
RP105−/− mice was restricted to arterial cells only. Proliferation rate and migration were measured over 16 h 
time period. (b) Venous VSMCs isolated from WT and RP105−/− mice produce significantly higher amounts of 
inflammatory cytokines IL6 and MCP1. Cells were maintain in culture for 14 days. *P < 0.05; n = 3.
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Increased expression of the pro-inflammatory mediators IL6, TNF and MCP1 are associated with AVF fail-
ure8, 40, 41, while the reduction of anti-inflammatory molecule heme oxygenase-1 (HO-1) is linked to AVF fail-
ure42–44. In our study, we demonstrated that the polarization of macrophages isolated from the bone marrow 
of RP105−/− mice towards the pro- or anti- inflammatory phenotypes appears to remove a regulatory repres-
sor, as both phenotypes displayed an up regulation of signature cytokines being produced. The augmentation of 
pro-inflammatory cytokine production in RP105−/− macrophages is in keeping with RP105 being an antagonist 
of pro-inflammatory TLR4 signaling25, 27, 45, while the spike in IL10 production is supported by recent reports that 
low grade inflammation triggers bone marrow-derived macrophages to generate anti-inflammatory cytokines in 
a TLR4 dependent fashion46.
AVF placement in RP105−/− mice yielded decreased MAC3+/CCR2+ macrophages and CD3+ T-lymphocytes. 
Our previous study performed by Wezel et al. on the role of RP105 in atherosclerosis showed the same difference 
which was linked to decrease in CCR2+ monocytes in RP105−/− mice hampering process of monocyte infiltration 
into the lesions. After additional in vitro stimulation with LPS the dose dependent decrease in CCR2 expression 
on CCR2+ monocytes isolated from RP105−/− mice was observed which may point onto increased signaling via 
TLR4 route29. A noteworthy observation two weeks after AVF placement in RP105−/− mice was the attenuation of 
vessel wall MMP activity. While the type of vascular injury impacts the degree by which MMPs remodel the vas-
cular wall, these factors also play a role in determining which MMPs are activated46, 47, and could differ between 
arterial and venous segments. Castier et al. reported that increased MMP-9 activity coincided with increased 
OR in the arterial segment of the AVF48, while Nieves Torres et al. demonstrated that MMP inhibition enhanced 
Figure 6. Effects of RP105 deficiency on inflammatory response in vivo. Quantification and 
immunohistochemical staining of (a) MAC3+/CCR2+  macrophages and MAC3+/CD206+ macrophages (white 
arrows) and (b) CD3+ T-lymphocytes (black arrows) in AVF lesions 14 days after surgery. Decrease in cell 
number of pro-inflammatory macrophages and upregulation in anti-inflammatory macrophages upon RP105 
deletion was observed. Bar = 100 μm. Number of CD3 T-lymphocytes was reduced in RP105 as compared to 
WT. Bar = 50 μm; 400x magnification. *P < 0.05; n = 11 per group.
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venous OR in AVF49. Our studies contradict this finding, and suggest instead that decreased MMP limits venous 
OR in maturating AVFs.
During the process of vascular remodeling the initial pro-inflammatory reaction is gradually changing 
towards resolution of inflammation characterized by accumulation of anti-inflammatory cells50–53. The specific 
dynamics with regard to pro-/anti- inflammatory response in the context of AVF maturation is still unknown. 
In our murine model, RP105 deficiency caused significant increase in MAC3+/CD206+ anti-inflammatory 
macrophages in the venous lesions of AVF, compared to controls. Overall prevalence in anti-inflammatory 
population (93.7%), compared to 6.3% of pro-inflammatory macrophages at 2 weeks after AVF creation might 
suggest either that in the current model pro-inflammatory response is completed at earlier time points or that 
anti-inflammatory macrophages play a dominant role in the tissue response in murine AVF. Thus, despite the 
increased production of both pro- and anti-inflammatory cytokines by macrophages in vitro, the effect of RP105 
deletion on anti- inflammatory macrophages was dominant in the venous lesions of murine AVF.
Figure 7. In vivo near-infrared biofluorescent imaging and quantitative analysis of MMP activity. (a) 
Quantitative analysis of fluorescent intensity showed decrease in MMP activity in RP105 mice, as compared to 
WT. (b) Visual representation of near-infrared signal from active MMPs. Accumulation of green color can be 
seen in the anastomotic region 24 h after injection of MMPSenseTM 680 probe. *P < 0.05; n = 4 per group.
Figure 8. Effect of RP105 deficiency on macrophage function. (a) Bone marrow-derived macrophages from 
RP105 primed towards pro-inflammatory phenotype secrete increased levels of MCP1 and IL6 as compared to 
WT control mice. (b) Anti-inflammatory macrophages from RP105 secrete increased levels of repair associated 
cytokine IL10. *P < 0.05; n = 3.
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Finally, to our knowledge it is the first study to demonstrate expression of RP105 in human AVF, which is an 
important observation supporting further research related to RP105 as a potential therapeutic target to improve 
AVF maturation.
Study limitations. Current study is performed in mice, which do not precisely mimic the human inflam-
matory response to injury; however this model remains highly useful for studying the vital pathophysiological 
aspects of AVF maturation and failure. Another limitation is the absence of uremia, given that a recent in vivo 
study by Kang et al. demonstrated that fistula maturation in mice is affected by CKD44. Here, the chronic accu-
mulation of waste products and uremic toxins in the blood impacted AVF flow, resulting in increased venous wall 
thickness and thrombus formation. Also, future studies should include flow measurements, as the rate of blood 
flow is critical functional parameter of AVF.
In conclusion, our study demonstrates the complex role of RP105 in VSMCs and macrophages in a murine 
model of AVF. The design and implementation of therapeutic strategies targeting the TLR4/RP105 axis to prevent 
AVF failure must include cell specific targeting approaches and be temporally controlled.
Material and Methods
Animals. Murine model of AVF failure. This study was performed in compliance with Dutch government 
guidelines and the Directive 2010/63/EU of the European Parliament. All animal experiments were approved by 
the Institutional Committee for Animal Welfare of Leiden University Medical Center. RP105−/− mice (C57BL/6 
background) were obtained from the local animal breeding facility, WTC57BL/6 mice were obtained from 
Charles River. Adult male mice aged 10–11 weeks were used for the experiments. AVF were created in an end-
to-side manner between the dorsomedial branch of the external jugular vein and the common carotid artery as 
previously described5, 54 (Supplementary Methods S1). The mice were euthanized at 2 weeks after AVF surgery.
In vivo near-infrared MMPs assay. In vivo MMP activity of endogenous MMP-2, -3, -9, -12 and -13 was assessed 
by injecting fluorescent imaging agent MMPSenseTM 680 from PerkinElmer’s (Waltham, MA, USA) which is acti-
vated in the presence of active MMPs55. First, AVF was created as described above (n = 4 per group). 14 days later 
mice were anesthetized under isoflurane and 4 nmol of MMPSenseTM 680 probe were injected into the tail vein. 
24 hours later, mice were placed under anesthesia, AVF was dissected and mice were scanned using the Optix 
MX2 optical imaging system. Excitation was performed with a 670-nm pulsing laser, and emission was detected 
with a 693-nm long-pass filter. Lifetime analysis was used to confirm the specificity of MMP-activated probes. 
Fluorescence intensities and fluorescence lifetime were expressed in pseudo colors and projected on the bright 
field grayscale image of the mouse. Quantification of the fluorescent intensity was performed using the Optiview 
2.2 software as described previously56.
Tissue harvesting and processing. 14 days after surgery, the mice were anesthetized using isoflurane whereupon 
the AVF was dissected. After a thoracotomy, the inferior vena cava was transsected followed by a mild pressure 
perfusion fixation with 4% formalin through an intracardiac perfusion. The tissue was embedded in paraffin and 
5 μm-thick sections of the venous outflow tract were made perpendicular to the vein with an interval of 150 μm.
Morphometric and histological analysis. Morphometric analysis was performed on Weigert’s elastin stained 
sections using ImageJ software. Vessel circumference as a parameter displaying the process of outward remod-
eling was determined by measuring the length of the internal elastic lamina (IEL). The intimal hyperplasia was 
calculated by subtracting the luminal area from the area within the IEL. Immunohistochemical staining was 
performed for macrophages (MAC3, 1:200, BD- Pharmingen, SanDiego, USA) in a combination with CCR2 for 
pro-inflammatory phenotype (1:400, Abcam, Cambridge, UK) or CD206 (1:1000, Abcam) for anti-inflammatory 
phenotype, T-lymphocytes (CD3, 1:300, Abcam) and VSMCs (αSMA, 1:1000, Dako, Glostrup, Denmark) in a 
combination with Ki67 (1:200, Abcam) to detect proliferating cells. For the immunohistochemical analysis of the 
MAC3/CD206, MAC3/CCR2 and αSMA/Ki67 staining, the number of positive cells was counted in 3 random 
fields of view using a 400x magnification from which the mean was calculated. Quantification of CD3+ cells was 
Figure 9. RP105 expression in human AVF. RP105 is highly expressed within the venous neointimal lesions of 
human AVF n = 4.
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performed with ImageJ software by calculating % DAB positive area from the total vessel area. All immunohis-
tochemical quantifications were performed on the first 3 venous sections starting from the anastomosis per AVF. 
Slides were digitized using an automated microscopic scanner (Panoramic digital MIDI, 3DHISTECH, Hungary). 
Results are expressed as mean ± standard error of the mean.
Cell culture. Vascular smooth muscle cells. Primary arterial and venous vascular smooth muscle cells were 
isolated from murine carotid artery and vena cava of C57Bl/6 and RP105−/− mice (n = 3 per group) respectively. 
Connective tissues were removed and vessels cut open. Endothelial monolayer was detached by gentle scraping 
with sterile surgical forceps. The carotid artery and caval vein were dissected into small pieces and plated onto 
Petri dish 100 mm or 60 mm diameter coated with 0.1 mg/ml fibronectine. After 14 days of culture with DMEM 
medium supplemented with 20% FCS, 2 mmol/l l-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, 
cells were trypsinized and re-plated onto 6 or 12 well plates and left for 7 days in culture. Upon enrichment in 
80–90% confluence VSMCs were trypsinized and seeded at required density for further functional assays.
Macrophages. Macrophages were derived from bone marrow by flushing tibia and femur of healthy C57Bl/6 
or RP105−/− mice (n = 3 per group) and seeded at a density of 500.000 cells/well in 6- wells plates. Cells were cul-
tured for 7 days in RPMI GlutaMax (Gibco) supplemented with 100 U/ml penicillin/streptavidin, 25% Fetal Calf 
Serum (FCS) and 20 mg/ml M-CSF (Myltec Biotechnologies) as described previously6. On day 7, cells were stim-
ulated either with LPS (100 ng/ml) and IFN-gamma (10 ng/ml) to differentiate them towards pro-inflammatory 
phenotype or with IL4 (10 ng/ml) and IL13 (10 ng/ml) (all from Preprotech) for anti-inflammatory pheno-
type. After 24 hours the supernatants were collected for ELISA assays and cells were lysed with Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) for RNA isolation.
VSMC proliferation assay. Murine VSMCs, explanted from aortas and veins of control or RP105−/− mice, 
were subsequently cultured as described above, and proliferation was measured using neutral red cell prolifera-
tion and cytotoxicity assay kit from Boster Bio (Pleasanton, CA, USA) according to the manufacturer protocol 
(Supplementary Methods S2).
VSMC migration assay. Primary arterial and venous VSMCs from control and RP105−/− mice were grown 
to confluence and then made quiescent in cultured medium supplemented with 1% FCS for 24 hours. Cells were 
detached from the surface using Accutase Cell Detachement Solution (Innovative Cell Technologies, Inc., San 
Diego, CA, USA) and suspended at a concentration of 100.000 cells/ml in culture medium supplemented with 1% 
FCS. Migration was assayed with a polycarbonate membrane inserts having 8 μm-pores in 24-well chemotaxis 
chambers using commercial CytoSelect Cell Migration Assay Kit (Cell Biolabs, Inc., San Diego, CA, USA) over 
16 hours towards the 20% FCS gradient. All migratory cells were lysed and labeled with fluorescent dye (CyQuant 
GR). Quantification was performed on a fluorescence plate reader at 480 nm/520 nm.
ELISA assays. ELISA assays for MCP1, IL6 and IL10 production were performed with cell free supernatant 
collected from bone marrow-derived macrophages after 24 hours polarization towards pro- or anti-inflammatory 
phenotype or ex vivo cultured arterial and venous VSMCs using commercial available kits following the instruc-
tions of the manufacturer (BD Biosciences, San Jose, CA, USA: MCP1- Catalog No. 555260; IL6- Catalog No. 
555240, IL10- Catalog No. 555252).
RT-PCR. Total RNA was extracted from the macrophages and VSMCs using Trizol reagent (Invitrogen) 
according to the manufacturer’s protocol. RNA was reverse transcribed using a 5-minute 65 °C incubation of 
1 µg total RNA with deoxyribonucleotide triphosphates (Invitrogen) and random primers (Invitrogen). c-DNA 
was synthesized using an M-MLV First-Strand Synthesis system (Invitrogen), and used for quantitative analysis 
of mouse genes (Supplementary Table 1) with an SYBR Green Master Mix (Applied Biosystems, Foster City, 
CA, USA). The relative mRNA expression levels were determined by normalization to murine glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) using 2[−ΔΔC(T)] method.
Statistical analysis. Results are expressed as mean ± SEM and considered statistically significant for 
p < 0.05; t tests and Mann-Whitney tests for parametric and nonparametric data, respectively, were used as 
appropriate. All in vitro experiments were performed in biological n = 3 in experimental triplicates.
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